Insulin pump therapy in the 21st century

References

• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial (DCCT) Research Group. N Engl J Med 1993; 329(14): 977–86
   PubMed Web of Science ®Google Scholar
• Scholtz HE, van Niekerk N, Meyer BH, et al. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique. (Abstr 882) Diabetologia 1999; 42(Suppl 1): 882
   Google Scholar
• Binder C, Lauritzen T, Faber O, et al. Insulin pharmacokinetics. Diabetes Care 1984; 7(2): 188–99
   PubMed Web of Science ®Google Scholar
• Pickup JC, Keen H, Parson JA, et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1978; 1(6107): 204–7
   PubMed Web of Science ®Google Scholar
• Tamborlane WV, Sherwin RS, Genel M, et al. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979; 300(11): 573–8
   PubMed Web of Science ®Google Scholar
• Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18(3): 361–76
   Google Scholar
• Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 1996; 19(4): 324–7
   PubMed Web of Science ®Google Scholar
• Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion: a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22(11): 1779–84
   PubMed Web of Science ®Google Scholar
• Chantelau E, Spraul M, Mühlhauser I, et al. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 1989; 32(7): 421–6
   PubMed Web of Science ®Google Scholar
• Rudolph JW, Hirsch IB. An assessment on continuous subcutaneous insulin infusion therapy in an academic diabetes clinic. (Abstr 501) Diabetes 2000; 49(Suppl 1): 501
   Google Scholar
• Bode BW, Sabbah HT, Gross TM, et al. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metal Res Rev 2001; 17: S1–8
   Google Scholar
• Bode B, Steed D, Davidson P. Determinants of glycemic control in insulin pump therapy. (Abstr 143) Diabetes 1997; 46(Suppl 1): 143
   Google Scholar
• Bode B, Steed R, Davidson P. Continuous subcutaneous insulin infusion (CSII): a study comparing lispro to regular human insulin. (Abstr 167) Diabetes 1997; 46(Suppl 1): 43A
   Google Scholar
• Zinman B, Tildesley H, Chiasson JL, et al. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997; 46(3): 440–3
   PubMed Web of Science ®Google Scholar
• Renner R, Pfützner A, Trautmann M, et al. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 1999; 22(5): 784–8
   PubMed Web of Science ®Google Scholar
• Davidson PC, Jeng L, Ghegan M, et al. Continuous subcutaneous insulin infusion for treatment of type 2 diabetes mellitus. (Abstr 796) Diabetologia 1999; 42(Suppl 1): 796
   Google Scholar
• Jennings AM, Lewis KS, Murdoch S, et al. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas. Diabetes Care 1991; 14(8): 738–44
   Google Scholar
• Wainstein J, Metzger M, Wexler ID, et al. The use of continuous insulin delivery systems in severely insulin-resistant patients. Diabetes Care 2001; 24(7): 1299
   Google Scholar
• Raskin P, Bode B, Marks JB, et al. Insulin aspart (IAsp) is as effective in continuous subcutaneous insulin infusion as in multiple daily injections for patients with type 2 diabetes. Diabetes 2001; 50(Suppl 2): A128
   Google Scholar
• Testa MA, Hayes JF, Turner RR, et al. Patient acceptance and satisfaction with intensive insulin therapy in type 2 diabetes: a randomized trial of the insulin pen vs pump. (Abstr 1781-PO) Diabetes 2001; 50(Suppl 2): A428
   Google Scholar
• Purnell JQ, Hokanson JE, Marcovina SM, et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; 280(2): 140–6
   PubMed Web of Science ®Google Scholar
• Bode BW, Gross TM, Ghegan M, et al. Breaking the age barrier: a comparison of continuous subcutaneous insulin infusion in adolescents and adults. (Abstr 227) Diabetologia 1999; 42(1): 227
   Google Scholar
• Steindel BS, Roe TR, Costin G, et al. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diabetes Res Clin Pract 1995; 27(3): 199–204
   Google Scholar
• Blackett PR. Insulin pump treatment for recurrent ketoacidosis in adolescence. (Letter) Diabetes Care 1995; 18(6): 881–2
   Google Scholar
• Graff MR, Rubin RR, Walker EA. How diabetes specialists treat their own diabetes: findings from a study of the AADE and ADA membership. Diabetes Educ 2000; 26(3): 460–7
   Google Scholar
• Bode BW, Gross T, Steed D, et al. A recent assessment of continuation rates for continuous subcutaneous insulin infusion (CSII). (Abstr 393) Diabetes 1998; 21(Suppl 1): 393
   Google Scholar
• Bode BW, Gross T, Ghegan MD, et al. Factors affecting the reduction of starting insulin dose in CSII. (Abstr 264) Diabetes 1999; 48(Suppl 1): 264
   Google Scholar
• Fredrickson L, Rubin RR, Rubin S. Optimal pumping: a guide to good health with diabetes. Northridge, Calif: Mini Med, 2001: 14–20
   Google Scholar
• Bode BW, Gross TM, Thornton KR, et al. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract 1999; 46(3): 183–90
   PubMed Web of Science ®Google Scholar
• Bode BW, Sabbah H, Davidson PC. What's ahead in glucose monitoring? Postgrad Med 2001; 109(4): 41–9
   PubMed Web of Science ®Google Scholar
• Ahern JH, Boland EA, Doane R, et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes (in press)
   Google Scholar
• Tubiana-Rufi N, de Lonlay P, Bloch J, et al. [Remission of severe hypoglycemia incidents in young diabetic children treated with subcutaneous infusion.] Arch Pediatr 1996; 3(10): 969–76 (Fre)
   Google Scholar
• de Beaufort CE, Houtzagers CM, Bruining GJ, et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow-up of a randomized, prospective trial. Diabetic Med 1989; 6(9): 766–71
   Google Scholar
• Buckingham BA, Paguntalan H, Fassl B, et al. Continuous subcutaneous insulin infusion (CSII) in children under five years of age. (Abstr 428-P) Diabetes 2001; 50(Suppl 2): 428
   Google Scholar
• Kaufman FR, Kim C, Halvorson M, et al. Use of insulin pump therapy at nighttime only for children 7–10 years of age with type 1 diabetes. Diabetes Care 2000; 23(5): 579–82
   Google Scholar